CMBA
BHVN

C.M. Bidwell & Associates’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

C.M. Bidwell & Associates’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,000
Closed -$138K – 636
2021
Q4 		$138K Sell
1,000
-1,135
-53% -$144K 0.08% 217
2021
Q3 		$297K Buy
+2,135
New +$267K 0.2% 89

Other funds holding BHVN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

C.M. Bidwell & Associates's BHVN Position: Q1 2022 in Review

C.M. Bidwell & Associates sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2022, closing a stake of 1,000 shares — an estimated $138K sold.

C.M. Bidwell & Associates first reported a position in BHVN in Q3 2021 and held it in 2 quarters. The position peaked at $297K in Q3 2021. 307 funds tracked by Wall St. Rank hold BHVN as of Q1 2022.

  • C.M. Bidwell & Associates reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2022 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 1,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2022, an estimated $138K.
  • C.M. Bidwell & Associates first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021 and held it in 2 quarters.
  • C.M. Bidwell & Associates's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $297K in Q3 2021.
  • 307 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2022.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2022, filed 29 Apr 2022.